jama glp-1 This one has been on my mind because I’ve seen this in my own patients., A new study in Psychiatry found that nearly 1 in 3 patients with eating disorders have used a injection — more than JAMA Internal Medicine on X:

Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach

Medicaid Spending on GLP-1 Drugs by State Nationally, Medicaid spending on GLP-1s totaled $3.5 billion between November 2023 and October 2024, averaging $48 per Medicaid enrollee

Key Highlights FDA approval and US launch of generic Saxenda (liraglutide injection) First-ever generic GLP-1 indicated for weight loss in the US market Teva's fifth first-to-market generic launch this year Indicated for adults with obesity or overweight and pediatric patients (12-17 years) with obesity Incidence and Prevalence Global Prevalence of Obesity: Latest Estimates The prevalence of obesity is increasing globally, with a particularly significant rise observed over the past decades in Western and Westernizing countries where rates have more than doubled in the last decade

Fear not

After each injection, the medication gradually releases into the bloodstream and influences the brain centers responsible for hunger and satiety